1
|
Diakite B, Kassogue Y, Dolo G, Wang J, Neuschler E, Kassogue O, Keita ML, Traore CB, Kamate B, Dembele E, Nadifi S, Murphy RL, Doumbia S, Hou L, Maiga M. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. BMC MEDICAL GENETICS 2020; 21:206. [PMID: 33076844 PMCID: PMC7574232 DOI: 10.1186/s12881-020-01133-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 09/24/2020] [Indexed: 12/21/2022]
Abstract
Background The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis in order to assess the association of p.Arg72Pro variant of P53 gene with the risk of breast cancer. Methods Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Case-control studies with age-matched on breast cancer havingevaluated the genotype frequencies of the TP53 p.Arg72Pro polymorphism were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot. Results Twenty-one publications with 7841 cases and 8876 controls were evaluated in this meta-analysis. Overall, our results suggested that TP53 p.Arg72Pro was associated with the risk of breast cancer for the dominant model (OR = 1.09, 95% CI = 1.02–1.16, P = 0.01) and the additive model (OR = 1.09, 95% CI = 1.01–1.17, P = 0.03), but not for the recessive model (OR = 1.07, 95% CI = 0.97–1.18, P = 0.19). According to the ethnic group analysis, Pro allele was associated with the risk of breast cancer in Caucasians for the dominant model and additive model (P = 0.02), and Africans for the recessive model and additive model (P = 0.03). Conclusions This meta-analysis found a significant association between TP53 p.Arg72Pro polymorphism and the risk of breast cancer. Individuals carrying at least one Pro allele were more likely to have breast cancer than individuals harboring the Arg allele.
Collapse
Affiliation(s)
- Brehima Diakite
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali. .,Teaching Hospital Center of Point G, 333, Bamako, Mali. .,Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.
| | - Yaya Kassogue
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali.,Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA
| | - Guimogo Dolo
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali
| | - Jun Wang
- Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.,Institute for Global Health, Northwestern University, IL60611, Chicago, USA
| | - Erin Neuschler
- Department of Radiology, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA
| | - Oumar Kassogue
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali
| | | | - Cheick B Traore
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali
| | - Bakarou Kamate
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali
| | - Etienne Dembele
- Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.,Institute for Global Health, Northwestern University, IL60611, Chicago, USA
| | - Sellama Nadifi
- Hassan II University Aïn chock, 20000, Casablanca,19, Rue Tarik Ibnou Ziad,, Morocco
| | - Robert L Murphy
- Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.,Institute for Global Health, Northwestern University, IL60611, Chicago, USA
| | - Seydou Doumbia
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Teaching Hospital Center of Point G, 333, Bamako, Mali
| | - Lifang Hou
- Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.,Institute for Global Health, Northwestern University, IL60611, Chicago, USA
| | - Mamoudou Maiga
- Faculty of Medicine and Odontostomatology, 1805, Université des Sciences, des Techniques et des Technologies Sciences de Bamako (USTTB), Hamdallaye ACI, 2000, Bamako, Mali.,Preventive Medicine Department, Cancer Epidemiology and Prevention, Northwestern University, Chicago, IL, 60611, USA.,Institute for Global Health, Northwestern University, IL60611, Chicago, USA
| |
Collapse
|
2
|
Ghante MH, Jamkhande PG. Role of Pentacyclic Triterpenoids in Chemoprevention and Anticancer Treatment: An Overview on Targets and Underling Mechanisms. J Pharmacopuncture 2019; 22:55-67. [PMID: 31338244 PMCID: PMC6645347 DOI: 10.3831/kpi.201.22.007] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2018] [Revised: 03/06/2019] [Accepted: 05/20/2019] [Indexed: 12/22/2022] Open
Abstract
The incidences of cancer are continuously increasing worldwide, affecting life of millions of people. Several factors associated with the internal and external environment are responsible for this deadly disease. The key internal determinants like abnormal hormonal regulation, genetic mutations and external determinants such as lifestyle and occupational factors enhances onset of cancer. From the ancient time, plants were remained as the most trusted source of medicine for the treatment of diverse disease conditions. Extensive studies have been performed for the discovery of effective anticancer agent from the plant and still it is going on. Pentacyclic triterpenoids are biologically active phytochemicals having a different range of activities such as anti-inflammatory, hepatoprotective, anti-hypertensive, antiulcerogenic and anti-tumor. These compounds generally contain ursane, oleanane, lupane and friedelane as a chief skeleton of pentacyclic triterpenoids which are generally present in higher plants. Isoprene unit, phytochemical, with good antitumor/anticancer activity is required for the biosynthesis of pentacyclic triterpenoids. Mechanisms such as cytotoxicity, DNA polymerase inhibition, regulation of apoptosis, change in signal transductions, interfere with angiogenesis and dedifferentiation, antiproliferative activity and metastasis inhibition are might be responsible for their anticancer effect. Present review spotlights diverse targets, mechanisms and pathways of pentacyclic triterpenoids responsible for anticancer effect.
Collapse
Affiliation(s)
- Mahavir H Ghante
- Centre for Research in Pharmaceutical Sciences, Sharda Bhavan Education Society's Nanded Pharmacy College, Nanded 431605, Maharashtra, India
| | - Prasad G Jamkhande
- Centre for Research in Pharmaceutical Sciences, Sharda Bhavan Education Society's Nanded Pharmacy College, Nanded 431605, Maharashtra, India
| |
Collapse
|
3
|
Schuetz JM, Grundy A, Lee DG, Lai AS, Kobayashi LC, Richardson H, Long J, Zheng W, Aronson KJ, Spinelli JJ, Brooks-Wilson AR. Genetic variants in genes related to inflammation, apoptosis and autophagy in breast cancer risk. PLoS One 2019; 14:e0209010. [PMID: 30601841 PMCID: PMC6314637 DOI: 10.1371/journal.pone.0209010] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 11/28/2018] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Inflammation contributes to breast cancer development through its effects on cell damage. This damage is usually dealt with by key genes involved in apoptosis and autophagy pathways. METHODS We tested 206 single nucleotide polymorphisms (SNPs) in 54 genes related to inflammation, apoptosis and autophagy in a population-based breast cancer study of women of European (658 cases and 795 controls) and East Asian (262 cases and 127 controls) descent. Logistic regression was used to estimate odds ratios for breast cancer risk, and case-only analysis to compare breast cancer subtypes (defined by ER/PR/HER2 status), with adjustment for confounders. We assessed statistical interactions between the SNPs and lifestyle factors (smoking status, physical activity and body mass index). RESULTS AND CONCLUSION Although no SNP was associated with breast cancer risk among women of European descent, we found evidence for an association among East Asians for rs1800925 (IL-13) and breast cancer risk (OR = 2.08; 95% CI: 1.32-3.28; p = 0.000779), which remained statistically significant after multiple testing correction (padj = 0.0350). This association was replicated in a meta-analysis of 4305 cases and 4194 controls in the Shanghai Breast Cancer Genetics Study (OR 1.12, 95% CI: 1.03-1.21, p = 0.011). Further, we found evidence of an interaction between rs7874234 (TSC1) and physical activity among women of East Asian descent.
Collapse
Affiliation(s)
- Johanna M. Schuetz
- Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Anne Grundy
- CRCHUM (Centre de recherche du Centre hospitalier de l’Université de Montréal), Montreal, QC, Canada
- Department of Social and Preventive Medicine, Université de Montréal, Montreal, QC, Canada
| | - Derrick G. Lee
- Department of Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada
- Department of Mathematics, Statistics, and Computer Science, St. Francis Xavier University, Antigonish, NS, Canada
| | - Agnes S. Lai
- Department of Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Lindsay C. Kobayashi
- Harvard Center for Population and Development Studies, Harvard T. H. Chan School of Public Health, Cambridge, MA, United States of America
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States of America
| | - Harriet Richardson
- Department of Public Health Sciences, Queen's University, Kingston, ON, Canada
- Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen’s University, Kingston, ON, Canada
| | - Jirong Long
- Vanderbilt Epidemiology Centre, Vanderbilt University Medical Center, Nashville, TN, United States of America
| | - Wei Zheng
- Vanderbilt Epidemiology Centre, Vanderbilt University Medical Center, Nashville, TN, United States of America
| | - Kristan J. Aronson
- Department of Public Health Sciences, Queen's University, Kingston, ON, Canada
- Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen’s University, Kingston, ON, Canada
| | - John J. Spinelli
- Department of Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada
- School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
| | - Angela R. Brooks-Wilson
- Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada
| |
Collapse
|
4
|
Zhang J, Yang Y, Li W, Yan L, Zhang D, He J, Wang J. TP53 gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study. J Cancer 2019; 10:467-471. [PMID: 30719141 PMCID: PMC6360307 DOI: 10.7150/jca.27482] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Accepted: 12/08/2018] [Indexed: 02/07/2023] Open
Abstract
The TP53 gene plays a crucial role in the prevention of cancer formation, which is closely related to TP53 mutation. TP53 gene polymorphism rs1042522 C>G was largely investigated in various cancers, but its contribution to neuroblastoma is as yet undefined. Here, we evaluated the effect of the TP53 gene rs1042522 C>G polymorphism on the development of neuroblastoma in two different regions, with patients from hospitals in both North and South China. The clinical data involved 374 patients and 812 controls. The resulting odds ratios (ORs) and 95% confidence intervals (CIs) were used with a logistic regression model to determine the intensity of associations between the factors of interest. We found that the TP53 gene rs1042522 allele G was associated with a reduced risk of developing neuroblastoma. In our stratified analysis of age, sex, primary sites and clinical stages, we observed that male children, older than 18 months, with tumours derived from the mediastinum who had the rs1042522 CG/GG genotypes were at a decreased risk of developing neuroblastoma. These results indicate that the TP53 gene rs1042522 allele G may be a potential protective factor against neuroblastoma in Chinese children.
Collapse
Affiliation(s)
- Jiao Zhang
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
- ✉ Corresponding authors: Jiao Zhang, Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450052, Henan, China, Tel./Fax: (+86- 0371) 66279071, e-mail: ; Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China, Tel./Fax: (+86-020) 38076560, e-mail:
| | - Yang Yang
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
| | - Wenya Li
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
| | - Lizhao Yan
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
| | - Da Zhang
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
| | - Jing He
- Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
- ✉ Corresponding authors: Jiao Zhang, Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450052, Henan, China, Tel./Fax: (+86- 0371) 66279071, e-mail: ; Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China, Tel./Fax: (+86-020) 38076560, e-mail:
| | - Jiaxiang Wang
- Department of Pediatric Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
| |
Collapse
|
5
|
Üren N, Korak T, Altınok D, Ergül E, Güllüoğlu B, Şimşek T, Cantürk Z, Utkan Z, Sazcı A. Meme Kanserinde TP53 (RS1042522) Polimorfizmi. KOCAELI ÜNIVERSITESI SAĞLIK BILIMLERI DERGISI 2016. [DOI: 10.30934/kusbed.358489] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
6
|
Askari M, Sobti RC, Nikbakht M, Sharma SC. Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Mol Cell Biochem 2013; 382:19-26. [PMID: 24005533 DOI: 10.1007/s11010-013-1696-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Accepted: 05/16/2013] [Indexed: 10/26/2022]
Abstract
p21 (Waf-1) is a cyclin-dependent kinase inhibitor that plays essential roles in cell growth arrest, terminal differentiation, and apoptosis. Statistically significant difference in the level of methylation of p21/CIP1 (p < 0. 05) between the patients with breast cancer and the healthy controls was observed. Risk of breast cancer was increased in patients with hypermethylated p21/CIP1 promoter by 2.31-fold (OR = 2.31, 95 % CI 1.95-2.74). The downregulation of p21/CIP1 mRNA expression was statistically significant in patients with methylated promoter (p < 0.00) in comparison to patients with unmethylated genes. Downregulation of mRNA expression of p21/CIP1 was up to 79% due to promoter hypermethylation. We examined several p21/CIP1 genotypes in the patients with breast cancer and found that there is no significant association of these p21/CIP1 genotypes with the risk of developing breast cancer. However, a significant 2.21-fold increase in the chance of developing breast cancer was observed in the candidates carrying at least one allele Arg mutant in p21/CIP1 genotype (i.e., Ser/Arg + Arg/Arg) with age >50 (OR = 2.21; 95 % CI 1.03-4.79).
Collapse
Affiliation(s)
- Marjan Askari
- Department of Biotechnology, Panjab University, Chandigarh, India
| | | | | | | |
Collapse
|
7
|
Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Epistatic interaction of Arg72Pro TP53 and −710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival. Mol Cell Biochem 2013; 379:181-90. [DOI: 10.1007/s11010-013-1640-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Accepted: 03/28/2013] [Indexed: 01/30/2023]
|
8
|
Hou J, Jiang Y, Tang W, Jia S. p53 codon 72 polymorphism and breast cancer risk: A meta-analysis. Exp Ther Med 2013; 5:1397-1402. [PMID: 23737888 PMCID: PMC3671901 DOI: 10.3892/etm.2013.1019] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2013] [Accepted: 03/12/2013] [Indexed: 12/21/2022] Open
Abstract
p53 is a tumor suppressor gene and plays important roles in the etiology of breast cancer. Studies have produced conflicting results concerning the role of p53 codon 72 polymorphism (G>C) on the risk of breast cancer; therefore, a meta-analysis was performed to estimate the association between the p53 codon 72 polymorphism and breast cancer. Screening of the PubMed database was conducted to identify relevant studies. Studies containing available genotype frequencies of the p53 codon 72 polymorphism were selected and a pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the association. Sixty-one published studies, including 28,539 breast cancer patients and 32,788 controls were identified. The results suggest that variant genotypes are not associated with breast cancer risk (Pro/Pro + Arg/Pro vs. Arg/Arg: OR=1.016, 95% CI=0.931–1.11, P=0.722). The symmetric funnel plot, Egger’s test (P=0.506) and Begg’s test (P=0.921) were all suggestive of the lack of publication bias. This meta-analysis suggests that the p53 codon 72 Pro/Pro + Arg/Pro genotypes are not associated with an increased risk of breast cancer. To validate the association between the p53 codon 72 polymorphism and breast cancer, further studies with larger numbers of participants worldwide are required.
Collapse
Affiliation(s)
- Jing Hou
- Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty
| | | | | | | |
Collapse
|
9
|
Sivoňová MK, Vilčková M, Jurečeková J, Hatok J, Dobrota D, Dušenka R, Kliment J. The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: a pilot study. Mol Med Rep 2012; 7:986-90. [PMID: 23292332 DOI: 10.3892/mmr.2012.1242] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Accepted: 11/28/2012] [Indexed: 11/05/2022] Open
Abstract
The cell cycle regulator p21 plays an important role in regulating critical cell activities including cell cycle control, DNA repair and apoptosis. Consequently, it may affect the efficacy of the response to DNA damage and tumor development. The aim of our study was to evaluate the frequencies of the p21 C70T polymorphism, the association between this genetic variant and smoking status, and the serum prostate-specific antigen (PSA) levels and Gleason score in 118 prostate cancer patients and 130 males routinely screened for prostate cancer in the Slovak population. Blood samples were collected from all individuals for DNA isolation, used for subsequent genotyping assays via PCR-RFLP methods. Overall, we did not observe any significant association between this polymorphism and prostate cancer risk. An analysis of the association between the p21 genotypes and smoking was then conducted. Among smokers, CC and CT genotypes were associated with a non‑significant increased risk (OR=1.48; 95% CI, 0.80-2.76 and OR=1.15; 95% CI, 0.27‑4.77, respectively; p>0.05) in comparison to non-smokers with the CC genotype. Patients with a CT genotype and serum PSA levels≥10 ng/ml had an 84% decrease in prostate cancer risk (OR=0.16; 95% CI, 0.03-0.75; p<0.05) compared to cases with serum PSA levels <10 ng/ml and the CC genotype. No significant association was detected between Gleason score and prostate cancer risk. Based on these results, we concluded that the p21 C70T polymorphism is associated with decreased risk of prostate cancer in Slovak men. To confirm these findings, a systematic approach is required to identify sequence variants in this and other related genes, and subsequently, to test for an association between such variants, smoking status and tumor-specific clinicopathological characteristics in large samples.
Collapse
Affiliation(s)
- Monika Kmetová Sivoňová
- Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, and University Hospital of Martin, Martin, Slovak Republic
| | | | | | | | | | | | | |
Collapse
|
10
|
Cheng H, Ma B, Jiang R, Wang W, Guo H, Shen N, Li D, Zhao Q, Wang R, Yi P, Zhao Y, Liu Z, Huang T. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis. Mol Biol Rep 2012; 39:9265-74. [PMID: 22729912 DOI: 10.1007/s11033-012-1800-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Accepted: 06/09/2012] [Indexed: 01/19/2023]
Abstract
The tumor suppressor gene TP53 and its negative regulator murine double minute 2 are involved in multiple cellular pathways. Two potentially functional single nucleotide polymorphisms (SNPs) MDM2 SNP309 and TP53 R72P have been extensively investigated to be associated with breast cancer risk. However, the original studies as well as the subsequent meta-analysis, have yielded contradictory results for the individual effect of the two SNPs on breast cancer risk, plus that conflicting results also existed for the combined effects of MDM2 SNP309 and TP53 R72P on breast cancer risk. This meta-analysis aimed to clarify the individual and combined effects of these two genes on breast cancer risk. We performed a meta-analysis of publications with a total 9,563 cases and 9,468 controls concerning MDM2 SNP309 polymorphism and 19,748 cases and 19,962 controls concerning TP53 R72P. Odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of the association. In overall meta-analysis, individuals with the MDM2 SNP309TG genotype were associated with a borderline higher breast cancer risk than those with TT genotype (OR = 1.11, 95 % CI: 1.00-1.24, P (heterogeneity) = 0.007), whereas the TP53 R72P CC or GC genotype had no effects on breast cancer risk. In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups. Moreover, no significant combined effects of MDM2 SNP309 and TP53 R72P were observed on breast cancer risk. The borderline association between MDM2 SNP309 and breast cancer risk in overall analysis should be treated with caution, and no significant combined effects for the two SNPs on breast cancer risk suggested functional investigations warranted to explore the molecular mechanism of the TP53-MDM2 circuit genes.
Collapse
Affiliation(s)
- Hongtao Cheng
- Department of Breast Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, Wang W, Arparkorn K. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 2011; 130:517-29. [PMID: 21604156 DOI: 10.1007/s10549-011-1583-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2011] [Accepted: 05/09/2011] [Indexed: 12/18/2022]
Abstract
p53 is a tumor suppressor gene and plays an important role in the etiology of breast cancer. However, studies on the association between p53 polymorphisms and breast cancer risk have yielded conflicting results. We performed a meta-analysis to investigate the association between breast cancer and the p53 polymorphisms codon 72 (27,046 cases and 30,998 controls), IVS3 16 bp (3,332 cases and 3,700 controls) and IVS6+62A>G (8,787 cases and 9,869 controls) in different inheritance models. When all the eligible studies of codon 72 polymorphism were pooled into this meta-analysis, there was no evidence of significant association between breast cancer risk and p53 codon 72 polymorphism in any genetic model. However, in the stratified analysis for Indian population, significantly association was observed in additive model (OR = 0.62, 95% CI = 0.46-0.82, P value of heterogeneity test [P (h)] = 0.153) and recessive model (OR = 0.70, 95% CI = 0.50-0.92, P (h) = 0.463). IVS3 16 bp was significantly associated with breast cancer risk in a pooled 15 studies dataset (dominant model: OR = 1.14, 95% CI = 1.02-1.27, P (h) = 0.30; recessive model: OR = 1.61, 95% CI = 1.21-2.25, P(h) = 0.25; additive model: OR = 1.66, 95% CI = 1.24-2.21, P (h) = 0.28). No significant association was found between IVS6+62A>G polymorphism and breast cancer risk in a total of 14 studies. In summary, these results indicate that IVS3 16 bp is likely an important genetic marker contributing to susceptibility of breast cancer, and codon 72 homozygous mutants may be associated with decreased breast cancer risk in Indian population.
Collapse
Affiliation(s)
- Xiao-Feng He
- Central Laboratory, Peace Hospital of Changzhi Medical College, Shanxi, 046000 China.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
BackgroundStudies investigating the association between p21 genetic polymorphism Ser31Arg and cervical cancer (CC) risk report conflicting results. The aim of this study was to quantitatively summarize the evidence for p21 polymorphism and CC risk.MethodsTwo investigators independently searched the MEDLINE, Embase, CNKI, and Chinese Biomedicine databases. Summary odds ratios (ORs) and 95% confidence intervals (CIs) for p21 polymorphism and CC were calculated in a fixed effects model (the Mantel-Haenszel method) and a random effects model (the DerSimonian and Laird method) when appropriate. The pooled ORs were performed for codominant model (Arg/Arg vs Ser/Ser and Arg/Ser vs Ser/Ser), dominant model (Arg/Arg + Arg/Ser vs Ser/Ser), and recessive model (Arg/Arg vs Arg/Ser + Ser/Ser). Subgroup analyses were performed by country, matched controls, and Hardy-Weinberg equilibrium in the controls and study sample size.ResultsThis meta-analysis included 10 case-control studies from an Asian population, which included 1415 CC cases and 1947 controls. Overall, the variant genotypes (Arg/Arg and Arg/Ser) of Ser31Arg were not associated with CC risk, when compared with the wild-type homozygote Ser/Ser (Arg/Arg vs Ser/Ser: OR, 1.30; 95% CI, 0.81-2.08; Arg/Ser vs Ser/Ser: OR, 1.06; 95% CI, 0.72-1.55). Similarly, no associations were found in the dominant and recessive models (dominant model: OR, 1.05; 95% CI, 0.73-1.51; recessive model: OR, 1.28; 95% CI, 0.86-1.90). Stratified analyses also detected no significant association in any subgroup, except among those studies from "other" country and those studies with controls deviated from Hardy-Weinberg equilibrium.ConclusionNo association was found between the p21 polymorphism Arg31Ser and risk of CC among Asians. In the future, additional studies based on white and African American patients should be performed to re-evaluate the association.
Collapse
|
13
|
Liu F, Li B, Wei Y, Chen X, Ma Y, Yan L, Wen T. P21 codon 31 polymorphism associated with cancer among white people: evidence from a meta-analysis involving 78 074 subjects. Mutagenesis 2011; 26:513-21. [DOI: 10.1093/mutage/ger010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|